AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors.
AvengeBio has raised $45.0M in total funding. The most recent round was Series A. The last funding was announced in January 2022.
AvengeBio's investors include Perceptive Advisors, Longitude Capital, Rock Springs Capital, Pappas Capital, CAM Capital.
AvengeBio is headquartered in Cambridge, United States.
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors.
AvengeBio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AvengeBio — Funding & Investors." VCBacked, January 5, 2022, https://www.vcbacked.co/company/avengebio. Accessed August 13, 2026.
VCBacked. (2022). AvengeBio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/avengebio
{{cite web |title=AvengeBio — Funding & Investors |url=https://www.vcbacked.co/company/avengebio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated